INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Pacira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until March 14, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you are an investor who purchased or otherwise acquired Pacira securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.        

[Click here for information about joining the class action] 

On August 9, 2024, Pacira announced that the U.S. District Court for the District of New Jersey, in a patent infringement lawsuit against eVenus Pharmaceutical Laboratories, Inc., had invalidated Pacira's '495 patent, covering its Exparel non-opioid pain treatment, on the basis of obviousness and anticipation.

 On this news, Pacira's stock price fell $10.66 per share, or 47.67%, to close at $11.70 per share on August 9, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-pacira-biosciences-inc-of-class-action-lawsuit-and-upcoming-deadlines--pcrx-302379480.html

SOURCE Pomerantz LLP